Estradiol dipropionate/hydroxyprogesterone caproate

{{Short description|Pharmaceutical combination}}

{{Drugbox

| image = Estradiol dipropionate.svg

| width = 250px

| caption =

| image2 = Hydroxyprogesterone caproate.svg

| width2 = 250px

| caption2 = Estradiol dipropionate (top) and hydroxy­progesterone caproate (bottom)

| type = combo

| drug_name = Estradiol dipropionate /
hydroxyprogesterone caproate

| component1 = Estradiol dipropionate

| class1 = Estrogen

| component2 = Hydroxyprogesterone caproate

| class2 = Progestogen

| tradename = EP Hormone Depot

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| DailyMedID =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Intramuscular injection

| CAS_number =

| CAS_supplemental =

| ATCvet =

| ATC_prefix = G03

| ATC_suffix = FA02

| ATC_supplemental =

| PubChem =

| PubChemSubstance = 17398112

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D04457

| ChEBI =

| ChEMBL =

| synonyms = EDP/OHPC

}}

Estradiol dipropionate/hydroxyprogesterone caproate (EDP/OHPC), sold under the brand name EP Hormone Depot, is a combined estrogen–progestogen medication which is used in Japan.{{Cite web |url=https://www.drugs.com/international/ep-hormone.html |title=Archived copy |access-date=2018-09-17 |archive-date=2019-04-07 |archive-url=https://web.archive.org/web/20190407210353/https://www.drugs.com/international/ep-hormone.html |url-status=dead }}{{cite journal | vauthors = Kawamura I, Mizota T, Lacey E, Tanaka Y, Manda T, Shimomura K, Kohsaka M | title = The estrogenic and antiestrogenic activities of droloxifene in human breast cancers | journal = Jpn. J. Pharmacol. | volume = 63 | issue = 1 | pages = 27–34 | date = September 1993 | pmid = 8271528 | doi = 10.1254/jjp.63.27 | doi-access = free }}{{cite journal | vauthors = Asanuma F, Yamada Y, Kawamura E, Lee K, Kobayashi H, Yamada T, Suzuki T, Kubota T | title = Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27 | journal = Folia Microbiol. (Praha) | volume = 43 | issue = 5 | pages = 473–4 | date = 1998 | pmid = 9821299 | doi = 10.1007/BF02820793 | s2cid = 22732235 }}{{cite journal | vauthors = Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I | title = Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7) | journal = Oncology | volume = 47 | issue = 1 | pages = 19–24 | date = 1990 | pmid = 2137212 | doi = 10.1159/000226779 | quote = After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week.}}{{cite journal | vauthors = Kubota T, Oka S, Utsumi T, Inoue S, Kuzuoka M, Suto A, Arisawa Y, Ishibiki K, Abe O | title = Human breast carcinoma (ZR-75-1) serially transplanted into nude mice--with reference to estradiol dependency and sensitivity to tamoxifen | journal = Jpn J Surg | volume = 19 | issue = 4 | pages = 446–51 | date = July 1989 | pmid = 2810959 | doi = 10.1007/BF02471626 | s2cid = 23267652 }}{{cite journal | vauthors = Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M | title = FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity | journal = J. Antibiot. | volume = 47 | issue = 3 | pages = 301–10 | date = March 1994 | pmid = 7513682 | doi = 10.7164/antibiotics.47.301 | doi-access = free }}{{cite journal | vauthors = Hori Y, Abe Y, Nishimura M, Goto T, Okuhara M, Kohsaka M | title = R1128 substances, novel non-steroidal estrogen-receptor antagonists produced by a Streptomyces. III. Pharmacological properties and antitumor activities | journal = J. Antibiot. | volume = 46 | issue = 7 | pages = 1069–75 | date = July 1993 | pmid = 8360101 | doi = 10.7164/antibiotics.46.1055 | doi-access = free }}{{cite journal | vauthors = Noguchi M, Koyasaki N, Miyazaki I, Mizukami Y | title = Effects of hormones on tumor growth and immunoreactive insulin-like growth factor-1 of estrogen receptor-positive human breast cancer (MCF-7) transplanted in nude mice | journal = Jpn. J. Cancer Res. | volume = 82 | issue = 11 | pages = 1199–202 | date = November 1991 | pmid = 1752778 | pmc = 5918318 | doi = 10.1111/j.1349-7006.1991.tb01780.x }} It is manufactured by Teikoku Zoki Pharmaceutical Co., Tokyo and contains 1 mg/mL estradiol dipropionate and 50 mg/mL hydroxyprogesterone caproate.